Americans Turning to AI to Supplement Healthcare Visits

A Gallup/West Health survey finds 25% of U.S. adults have used AI for health information, with 59% of recent users researching before doctor visits and 56% after visits. While AI appears to supplement care for most users, 14% of recent users say it led them to skip a provider visit, implying about 14 million adults nationwide. Trust remains limited: only 4% strongly trust AI health advice, and 11% say it recommended information they believed was unsafe.

Analysis

The important market implication is not “AI is being used for health,” but that consumer behavior is shifting upstream of the physician visit. That creates a new wedge between demand generation and clinical conversion: AI chat/search tools become the first triage layer, which can either funnel patients into higher-intensity care or suppress utilization entirely. The beneficiaries are likely the distribution layers that sit closest to the query layer—general-purpose AI assistants and search-integrated AI summaries—because they capture intent before patients enter a provider-owned workflow.

The more interesting second-order effect is on healthcare economics. If a meaningful share of low-income patients are substituting AI for paid visits, near-term utilization pressure falls first on urgent care, telehealth, cash-pay primary care, and high-deductible exposed services, not on high-acuity specialty care. Over months, that can mildly compress volumes in consumer-facing care models while increasing downstream complexity for clinicians who do see these patients, since they arrive pre-loaded with self-diagnoses and medication questions that lengthen visit time but may improve conversion to imaging, labs, or follow-up.

The contrarian read is that the headline risk is less misinformation than under-triage. A low-trust tool can still change behavior if it is “good enough” to delay care, especially for cost-constrained users. That argues for regulatory attention over a 6-18 month horizon: disclosure, liability standards, and payer/provider guardrails could slow adoption in healthcare-specific AI products, but are less likely to affect broad consumer AI platforms embedded in search. The market is probably underpricing that consumer AI search is the real healthcare gateway, while the direct-to-consumer healthcare AI category may be overhyped relative to its actual decision share.

Key Decisions for Investors

• Long MSFT / GOOGL on a 3-6 month horizon: both control high-frequency AI surfaces that capture health-intent traffic before provider systems do; prefer GOOGL if you want the cleaner lever to search-adjacent health queries, with downside capped if healthcare-specific scrutiny rises.
• Short small-cap telehealth/consumer primary-care names over 1-2 quarters on any AI-driven retail enthusiasm: AI substitution is a modest headwind to visit volume and a larger headwind to pricing power; use tight stops because the impact is behavioral, not structural.
• Pair long large-cap managed-care / pharmacy benefit exposure against short cash-pay care operators: if AI increases self-triage and generic medication research, payer scale and formulary control should win versus consumer clinics dependent on front-end traffic.
• Buy downside protection in healthcare AI vendors with pure-play 'patient engagement' narratives via put spreads 6-12 months out: the article supports adoption, but not strong willingness to pay or trust, which limits monetization and raises execution risk.
• Watch for a regulatory catalyst in the next 6-18 months: if policymakers move toward AI medical-advice labeling or liability rules, take profits on consumer AI health-adjacent enthusiasm and rotate into platforms with diversified revenue, not healthcare-specific tooling.